TNNT2 and breast carcinoma: Serum hs-cTnT level in patients with breast cancer after chemotherapy [13.5 (4.1–843.9) pg/mL] was increased compared with that before chemotherapy [7 (2,15) pg/mL], and the difference was statistically significant (P < 0.001) (Table 2).